Truth in science.
Transformation in medicine.
At Vera Therapeutics, we pursue truth in science to transform medicine in autoimmune diseases, starting with the kidney.
Rigorous science
We focus on upstream immune pathways that drive disease, asking hard questions and following the evidence.
Patient-centered
We listen closely to patients and caregivers, so their experiences help shape how we approach disease, not just how we measure it.
Designed with intention
Vera was designed to think long-term, with independent and disciplined focus on doing the work that meaningful progress requires.
OUR FOCUS
Committed to IgA nephropathy
We are deeply focused on IgA nephropathy, where the immune drivers of disease remain largely unaddressed and patient need is high.
FEATURED news
June 2, 2026
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
- PDUFA date of July 7, 2026 for BLA for accelerated approval of atacicept in patients with IgAN
- Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027
- Pending positive eGFR analysis, plans to submit an sBLA in Q4 2026, with potential full approval in 2027
Built on truth, driven by science
We challenge long-standing assumptions in nephrology by combining rigorous science with a deep respect for the lived experience to turn discovery into meaningful progress.
Patient stories
We listen to the lived experiences of people affected by disease. Their perspectives help shape how we pursue new approaches and measure progress.
Working at Vera Therapeutics
We move with purpose, uphold scientific rigor, and value the perspectives that help us see the whole human experience behind complex disease.
Investor & Media Relations
Access our investor and media relations center for company news, financial information, and resources for analysts and journalists.